Clinical Trial: Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07444814) titled 'Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors' on Feb. 11.

Brief Summary: HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.

Study Start Date: Dec. 19, 2025

Study Type: INTERVENTIONAL

Condition: Endometrial Cancer Ovarian Cancer Ovaria...